Literature DB >> 22345189

Tricuspid transcatheter valve-in-valve: an alternative for high-risk patients.

Diego Felipe Gaia1, José Honório Palma, José Augusto Marcondes de Souza, Enio Buffolo.   

Abstract

Tricuspid valve disease is not uncommon. Some patients with tricuspid valve disease require tricuspid replacement with bioprosthesis and, over time, may require re-interventions. Transcatheter tricuspid valve-in-valve approach has emerged as an alternative to treat dysfunctional bioprosthesis. In this article, we report a case of a patient with four previous cardiac interventions presenting with tricuspid bioprosthesis dysfunction. The patient was treated with the transcatheter transatrial tricuspid valve-in-valve procedure. The procedure was successful with no residual leakage and a non-significant mean gradient. The patient recovered well and was discharged in 1 week. The procedure is a feasible alternative for high-risk patients. Selection and postoperative care are crucial for the outcome.

Entities:  

Mesh:

Year:  2012        PMID: 22345189     DOI: 10.1093/ejcts/ezr038

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

1.  Transcatheter tricuspid valve-in-valve replacement: one-year results : Alternative to surgery in high-risk patients.

Authors:  João Mesquita; Rui Campante Teles; José Pedro Neves; João Abecasis; Pedro Carmo; João Brito; Miguel Abecasis; Manuel Sousa Almeida; Marisa Trabulo; Regina Ribeiras; Ricardo Seabra-Gomes; Miguel Mendes
Journal:  Heart Vessels       Date:  2016-11-15       Impact factor: 2.037

Review 2.  Which way in? The necessity of multiple approaches to transcatheter valve therapy.

Authors:  S Bleiziffer; M Krane; M A Deutsch; Y Elhmidi; N Piazza; B Voss; R Lange
Journal:  Curr Cardiol Rev       Date:  2013-11

3.  Transcatheter tricuspid valve-in-valve implantation in a dysfunctional bioprosthetic valve.

Authors:  Alper Güzeltaş; İbrahim Cansaran Tanıdır; Bekir Yükcü; Erman Cilsal; Murat Şahin
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-04-26       Impact factor: 0.332

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.